Simcere Beefs Up Sales Force, Carves Out Provincial Sales Strategy To Drive Growth In China

SHANGHAI- U.S.-listed Simcere Pharmaceutical is expanding its sales force in China for future growth and recently received Chinese regulatory approval for palonosetron, a second-generation 5-HT3 antagonist for the prevention and control of acute chemotherapy-induced nausea and vomiting, the company announced during its most recent earnings call